GT Biopharma Ownership 2024 | Who Owns GT Biopharma Now?


OverviewFinancialsChart

Institutional Ownership

0.00%

Insider Ownership

6.67%

Retail Ownership

93.33%

Institutional Holders

1.00

GT Biopharma Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RETIREMENT GROUP, LLC0.00%-1-43-97.73%4Mar 31, 2024
JPMORGAN CHASE & CO----16-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----1,073-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----300,719-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----32,347-100.00%-Mar 31, 2024
STATE STREET CORP----79,976-100.00%-Mar 31, 2024
VANGUARD GROUP INC----1,087,993-100.00%-Mar 31, 2024
GOLDMAN SACHS GROUP INC----22,867-100.00%-Mar 31, 2024
MORGAN STANLEY----8,078-100.00%-Mar 31, 2024
BANK OF MONTREAL /CAN/----596,240-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----114,695-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----337,315-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----65,953-100.00%-Mar 31, 2024
BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC----300-100.00%-Mar 31, 2024
BLACKROCK INC.----304,041-100.00%-Mar 31, 2024
BANK OF NEW YORK MELLON CORP----95,239-100.00%-Mar 31, 2024
LPL FINANCIAL LLC----34,320-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----57,807-100.00%-Mar 31, 2024
WELCH GROUP, LLC----10,000-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----37,180-100.00%-Mar 31, 2024

GT Biopharma's largest institutional shareholder is RETIREMENT GROUP, LLC, holding 0.00% of the company's total share outstanding, currently valued at $4.00. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RETIREMENT GROUP, LLC0.00%-1-43-97.73%4Mar 31, 2024
JPMORGAN CHASE & CO----16-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----1,073-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----300,719-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----32,347-100.00%-Mar 31, 2024
STATE STREET CORP----79,976-100.00%-Mar 31, 2024
VANGUARD GROUP INC----1,087,993-100.00%-Mar 31, 2024
GOLDMAN SACHS GROUP INC----22,867-100.00%-Mar 31, 2024
MORGAN STANLEY----8,078-100.00%-Mar 31, 2024
BANK OF MONTREAL /CAN/----596,240-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----114,695-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----337,315-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----65,953-100.00%-Mar 31, 2024
BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC----300-100.00%-Mar 31, 2024
BLACKROCK INC.----304,041-100.00%-Mar 31, 2024
BANK OF NEW YORK MELLON CORP----95,239-100.00%-Mar 31, 2024
LPL FINANCIAL LLC----34,320-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----57,807-100.00%-Mar 31, 2024
WELCH GROUP, LLC----10,000-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----37,180-100.00%-Mar 31, 2024

The largest GT Biopharma shareholder by % of total assets is RETIREMENT GROUP, LLC. The company owns 1.00 shares of GT Biopharma (GTBP), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
QUBE RESEARCH & TECHNOLOGIES LTD----2-100.00%-Mar 31, 2024
JPMORGAN CHASE & CO----16-100.00%-Mar 31, 2024
RETIREMENT GROUP, LLC0.00%-1-43-97.73%4Mar 31, 2024
BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC----300-100.00%-Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.----1,017-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----1,073-100.00%-Mar 31, 2024
MORGAN STANLEY----8,078-100.00%-Mar 31, 2024
WELCH GROUP, LLC----10,000-100.00%-Mar 31, 2024
UBS GROUP AG----14,605-100.00%-Mar 31, 2024
JANE STREET GROUP, LLC----19,405-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----19,775-100.00%-Mar 31, 2024
MOSS ADAMS WEALTH ADVISORS LLC----20,000-100.00%-Mar 31, 2024
GOLDMAN SACHS GROUP INC----22,867-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----32,347-100.00%-Mar 31, 2024
HRT FINANCIAL LP----33,785-100.00%-Mar 31, 2024
LPL FINANCIAL LLC----34,320-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----37,180-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----57,807-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----65,953-100.00%-Mar 31, 2024
STATE STREET CORP----79,976-100.00%-Mar 31, 2024

As of Mar 31 2024, GT Biopharma's largest institutional buyer is QUBE RESEARCH & TECHNOLOGIES LTD. The company purchased -2.00 stocks of GTBP, valued at -.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
VANGUARD GROUP INC----1,087,993-100.00%-Mar 31, 2024
BANK OF MONTREAL /CAN/----596,240-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----337,315-100.00%-Mar 31, 2024
BLACKROCK INC.----304,041-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----300,719-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----114,695-100.00%-Mar 31, 2024
ATRIA WEALTH SOLUTIONS, INC.----98,720-100.00%-Mar 31, 2024
BANK OF NEW YORK MELLON CORP----95,239-100.00%-Mar 31, 2024
STATE STREET CORP----79,976-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----65,953-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----57,807-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----37,180-100.00%-Mar 31, 2024
LPL FINANCIAL LLC----34,320-100.00%-Mar 31, 2024
HRT FINANCIAL LP----33,785-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----32,347-100.00%-Mar 31, 2024
GOLDMAN SACHS GROUP INC----22,867-100.00%-Mar 31, 2024
MOSS ADAMS WEALTH ADVISORS LLC----20,000-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----19,775-100.00%-Mar 31, 2024
JANE STREET GROUP, LLC----19,405-100.00%-Mar 31, 2024
UBS GROUP AG----14,605-100.00%-Mar 31, 2024

As of Mar 31 2024, GT Biopharma's biggest institutional seller is VANGUARD GROUP INC. The company sold -1.09M shares of GTBP, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
VANGUARD GROUP INC----1,087,993-100.00%-Mar 31, 2024
BANK OF MONTREAL /CAN/----596,240-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----337,315-100.00%-Mar 31, 2024
BLACKROCK INC.----304,041-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----300,719-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----114,695-100.00%-Mar 31, 2024
ATRIA WEALTH SOLUTIONS, INC.----98,720-100.00%-Mar 31, 2024
BANK OF NEW YORK MELLON CORP----95,239-100.00%-Mar 31, 2024
STATE STREET CORP----79,976-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----65,953-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----57,807-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----37,180-100.00%-Mar 31, 2024
LPL FINANCIAL LLC----34,320-100.00%-Mar 31, 2024
HRT FINANCIAL LP----33,785-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----32,347-100.00%-Mar 31, 2024
GOLDMAN SACHS GROUP INC----22,867-100.00%-Mar 31, 2024
MOSS ADAMS WEALTH ADVISORS LLC----20,000-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----19,775-100.00%-Mar 31, 2024
JANE STREET GROUP, LLC----19,405-100.00%-Mar 31, 2024
UBS GROUP AG----14,605-100.00%-Mar 31, 2024
WELCH GROUP, LLC----10,000-100.00%-Mar 31, 2024
MORGAN STANLEY----8,078-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----1,073-100.00%-Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.----1,017-100.00%-Mar 31, 2024
BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC----300-100.00%-Mar 31, 2024
JPMORGAN CHASE & CO----16-100.00%-Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD----2-100.00%-Mar 31, 2024

GT Biopharma's largest sold out institutional shareholder by shares sold is VANGUARD GROUP INC, sold -1.09M shares, valued at -, as of undefined.

GT Biopharma Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
VANGUARD VALLEY FORGE FUNDS0.03%16,775--Dec 31, 2023
DEUTSCHE DWS INVESTMENTS VIT FUNDS0.01%2,456--Dec 31, 2023
QUANTITATIVE MASTER SERIES LLC0.01%34,934--Dec 31, 2023
Fidelity Commonwealth Trust II0.00%32,905--Aug 31, 2023
VANGUARD INDEX FUNDS0.00%1,396,560315,88529.23%Dec 31, 2023
TIAA SEPARATE ACCOUNT VA 10.00%701--Dec 31, 2023
FIDELITY CONCORD STREET TRUST0.00%324,587--Feb 29, 2024
VARIABLE INSURANCE PRODUCTS FUND II0.00%17,977--Dec 31, 2023
AdvisorShares Trust0.00%2,426--Dec 29, 2023
Calvert Variable Products, Inc.0.00%1,870--Dec 31, 2023
SCHWAB CAPITAL TRUST0.00%25,869--Feb 29, 2024
STATE STREET VARIABLE INSURANCE SERIES FUNDS INC0.00%1,400--Dec 31, 2023
Voya VARIABLE PORTFOLIOS INC0.00%7,958--Dec 31, 2023
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%6,559--Dec 31, 2023
TIAA-CREF LIFE FUNDS0.00%453--Dec 31, 2023
T. Rowe Price Index Trust, Inc.0.00%1,081--Feb 29, 2024
FIDELITY SALEM STREET TRUST0.00%135,548--Feb 29, 2024
STATE STREET INSTITUTIONAL INVESTMENT TRUST0.00%4,200--Dec 31, 2023
ProFunds0.00%380--Jan 31, 2024
RYDEX SERIES FUNDS0.00%171--Dec 31, 2023
Invesco Exchange-Traded Self-Indexed Fund Trust0.00%7,201--Feb 29, 2024
PENN SERIES FUNDS INC0.00%900--Dec 29, 2023
VANGUARD SCOTTSDALE FUNDS0.00%59,063--Feb 29, 2024
RYDEX DYNAMIC FUNDS0.00%93--Dec 31, 2023
VALIC Co I0.00%6,577--Feb 29, 2024
Legg Mason Global Asset Management Trust0.00%18,707--Jan 31, 2024
Guggenheim Active Allocation Fund0.00%105--Feb 29, 2024
NATIONWIDE MUTUAL FUNDS0.00%2,259--Jan 31, 2024
NATIONWIDE VARIABLE INSURANCE TRUST0.00%2,317--Dec 31, 2023
COLLEGE RETIREMENT EQUITIES FUND0.00%17,029--Dec 31, 2023
RYDEX VARIABLE TRUST0.00%17--Dec 31, 2023
Goldman Sachs ETF Trust0.00%1,060--Feb 29, 2024
NORTHERN FUNDS0.00%9,466--Dec 29, 2023
PROSHARES TRUST0.00%2,557--Feb 29, 2024
MORGAN STANLEY PATHWAY FUNDS0.00%972--Feb 29, 2024
LINCOLN VARIABLE INSURANCE PRODUCTS TRUST0.00%19,100--Dec 31, 2023
VANGUARD WELLINGTON FUND0.00%2,547--Feb 29, 2024
Brighthouse Funds Trust II0.00%11,471--Dec 31, 2023
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%9,992--Dec 31, 2023
EQ ADVISORS TRUST0.00%5,278--Dec 31, 2023
iSHARES TRUST0.00%64,979--Feb 29, 2024
PACIFIC SELECT FUND0.00%7,617--Dec 31, 2023
MASSMUTUAL SELECT FUNDS0.00%1,653--Dec 31, 2023
SUNAMERICA SERIES TRUST0.00%500--Jan 31, 2024
BlackRock Variable Series Funds, Inc.0.00%2,844--Dec 31, 2023
PRINCIPAL FUNDS, INC.0.00%3,252--Feb 29, 2024
Bridge Builder Trust0.00%1,966--Dec 31, 2023
SEI INSTITUTIONAL INVESTMENTS TRUST0.00%5,100--Feb 29, 2024
BLACKROCK FUNDS0.00%1,529--Feb 29, 2024
John Hancock Funds II0.00%3,103--Feb 29, 2024

GT Biopharma's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 16.77K shares, compromising 0.03% of its total assets.

GT Biopharma Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 241-96.43%
31 Dec, 2328-
30 Sep, 2328-9.68%
30 Jun, 2331-6.06%
31 Mar, 23336.45%
31 Dec, 22313.33%
30 Sep, 2230-28.57%
30 Jun, 2242-23.64%
31 Mar, 22557.84%
31 Dec, 2151-3.77%
30 Sep, 215312.77%
30 Jun, 2147176.47%
31 Mar, 2117-
30 Jun, 201-

As of 31 Mar 24, 1 institutions are holding GT Biopharma's shares, representing a decrease of -96.43% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 241-100.00%
31 Dec, 233,393,512-0.46%
30 Sep, 233,409,0253.59%
30 Jun, 233,290,804-33.64%
31 Mar, 234,959,315-21.68%
31 Dec, 226,332,203156.51%
30 Sep, 222,468,639-19.09%
30 Jun, 223,051,112-31.45%
31 Mar, 224,450,713-17.32%
31 Dec, 215,383,33314.61%
30 Sep, 214,697,1704.60%
30 Jun, 214,490,786698.39%
31 Mar, 21562,481-
30 Jun, 20750-

GT Biopharma (GTBP) has 1.00 shares outstanding as of 31 Mar 24, down -100.00% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 240.00%-
31 Dec, 238.27%11.49%
30 Sep, 238.49%11.97%
30 Jun, 238.42%5.23%
31 Mar, 2312.69%3.21%
31 Dec, 2219.87%32.11%
30 Sep, 227.87%8.25%
30 Jun, 229.77%5.20%
31 Mar, 2213.70%4.66%
31 Dec, 2117.15%7.66%
30 Sep, 2114.97%8.34%
30 Jun, 2113.40%475.74%
31 Mar, 211.68%-
30 Jun, 200.00%-

As of 31 Mar 24, GT Biopharma is held by 0.00% institutional shareholders, representing a 0.00% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 24--100.00%
31 Dec, 231330.00%
30 Sep, 231011.11%
30 Jun, 239-18.18%
31 Mar, 2311-35.29%
31 Dec, 221788.89%
30 Sep, 229-30.77%
30 Jun, 2213-7.14%
31 Mar, 2214-54.84%
31 Dec, 213119.23%
30 Sep, 2126-36.59%
30 Jun, 2141141.18%
31 Mar, 2117-
30 Jun, 201-

- institutional shareholders have increased their position in GTBP stock as of 31 Mar 24 compared to 13 in the previous quarter (a -100.00% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 241-75.00%
31 Dec, 234-42.86%
30 Sep, 237-22.22%
30 Jun, 23912.50%
31 Mar, 23860.00%
31 Dec, 225-61.54%
30 Sep, 2213-31.58%
30 Jun, 2219-26.92%
31 Mar, 2226420.00%
31 Dec, 215-70.59%
30 Sep, 2117325.00%
30 Jun, 214-
31 Mar, 21--
30 Jun, 20--

1 institutional shareholders have reduced their position in GTBP stock as of 31 Mar 24 compared to 4 in the previous quarter (a -75.00% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 241-96.43%1-100.00%0.00%---100.00%1-75.00%
31 Dec, 2328-3,393,512-0.46%8.27%11.49%1330.00%4-42.86%
30 Sep, 2328-9.68%3,409,0253.59%8.49%11.97%1011.11%7-22.22%
30 Jun, 2331-6.06%3,290,804-33.64%8.42%5.23%9-18.18%912.50%
31 Mar, 23336.45%4,959,315-21.68%12.69%3.21%11-35.29%860.00%
31 Dec, 22313.33%6,332,203156.51%19.87%32.11%1788.89%5-61.54%
30 Sep, 2230-28.57%2,468,639-19.09%7.87%8.25%9-30.77%13-31.58%
30 Jun, 2242-23.64%3,051,112-31.45%9.77%5.20%13-7.14%19-26.92%
31 Mar, 22557.84%4,450,713-17.32%13.70%4.66%14-54.84%26420.00%
31 Dec, 2151-3.77%5,383,33314.61%17.15%7.66%3119.23%5-70.59%
30 Sep, 215312.77%4,697,1704.60%14.97%8.34%26-36.59%17325.00%
30 Jun, 2147176.47%4,490,786698.39%13.40%475.74%41141.18%4-
31 Mar, 2117-562,481-1.68%-17---
30 Jun, 201-750-0.00%-1---

GT Biopharma Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 11, 2023Breen Michael Martindirector, officer Executive Chairman/Interim CEOP-PurchaseBuy50,000$0.50$25.00K656,218
Apr 10, 2023Ohri Manuofficer CFO & SecretaryP-PurchaseBuy50,000$0.50$25.00K50,000

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 11, 2023Breen Michael Martindirector, officer Executive Chairman/Interim CEOP-PurchaseBuy50,000$0.50$25.00K656,218
Apr 10, 2023Ohri Manuofficer CFO & SecretaryP-PurchaseBuy50,000$0.50$25.00K50,000

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 15, 2023Ohri Manuofficer CFO & SecretaryJ-OtherSell200,000$0.29$57.40K-
Jul 19, 2022Ohri Manuofficer CFO & SecretaryJ-OtherSell100,000---

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 15, 2023Breen Michael Martindirector, officer Executive Chairman/Interim CEOA-AwardBuy200,000$0.29$57.40K856,218
Aug 15, 2023Ohri Manuofficer CFO & SecretaryJ-OtherBuy200,000$0.29$57.40K300,000
Aug 15, 2023Ohri Manuofficer CFO & SecretaryA-AwardBuy200,000$0.29$57.40K200,000
Aug 15, 2023Ohri Manuofficer CFO & SecretaryJ-OtherSell200,000$0.29$57.40K-
Jun 21, 2023CASAMENTO CHARLES Jdirector-A-AwardBuy500,000$0.35$175.00K500,000
May 04, 2023CASAMENTO CHARLES Jdirector Buy----
Apr 11, 2023Breen Michael Martindirector, officer Executive Chairman/Interim CEOP-PurchaseBuy50,000$0.50$25.00K656,218
Apr 10, 2023Ohri Manuofficer CFO & SecretaryP-PurchaseBuy50,000$0.50$25.00K50,000
Feb 01, 2023Breen Michael Martindirector, officer Exec Chairman and Interim CEOA-AwardBuy500,000$0.84$418.50K500,000
Feb 01, 2023Ohri Manuofficer Chief Financial OfficerA-AwardBuy500,000$0.84$418.50K500,000
Feb 01, 2023SHROTRIYA RAJESH C MDdirector-A-AwardBuy500,000$0.84$418.50K500,000
Feb 01, 2023Wendel Brucedirector-A-AwardBuy500,000$0.84$418.50K500,000
Jul 19, 2022Breen Michael Martinofficer Exec. Chair. and Interim CEOA-AwardBuy50,000--50,000
Jul 19, 2022SHROTRIYA RAJESH C MDdirector A-AwardBuy50,000--50,000
Jul 19, 2022URBAN ALAN LOUISdirector A-AwardBuy50,000--50,000
Jul 19, 2022URBAN ALAN LOUISdirector-A-AwardBuy50,000$2.48$124.00K50,000
Jul 19, 2022Berk Gregoryofficer Pres. of R&D, CMOA-AwardBuy50,000$2.48$124.00K50,000
Jul 19, 2022Berk Gregoryofficer Pres. of R&D, CMOA-AwardBuy50,000--50,000
Jul 19, 2022Ohri Manuofficer CFO & SecretaryA-AwardBuy200,000--200,000
Jul 19, 2022Ohri Manuofficer CFO & SecretaryJ-OtherSell100,000---

The last insider sell of GT Biopharma's stock was made by Ohri Manu on Aug 15 2023, selling 200,000 shares at $0.29 per share (valued at $57.40K). The last insider buy of GTBP was made by Breen Michael Martin on Apr 11 2023, buying 50,000 shares at $0.50 per share (worth $25.00K).

GT Biopharma Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 20232--
Q1 20234--
Q3 202261600.00%
Q2 2022---
Q1 2022---
Q4 20211--
Q1 202191900.00%
Q4 202031618.75%
Q2 2020-3-
Q3 20192--
Q1 2019-2-
Q4 2017-3-
Q3 20172366.67%
Q2 201611100.00%
Q1 2016-5-
Q1 20121--
Q3 20111--
Q2 20111250.00%
Q4 20102728.57%
Q3 2010-10-

2 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by GT Biopharma's insiders, as of Q2 2023.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 20232--
Q1 2023---
Q3 2022---
Q2 2022---
Q1 2022---
Q4 2021---
Q1 2021---
Q4 202031618.75%
Q2 2020-2-
Q3 2019---
Q1 2019-2-
Q4 2017---
Q3 2017---
Q2 2016-1-
Q1 2016---
Q1 2012---
Q3 2011---
Q2 20111--
Q4 2010-4-
Q3 2010-10-

As of Q2 2023, Insider owners conducted 2 open market buy trades and 0 open market sell trades of GT Biopharma's stocks.

GT Biopharma Peer Ownership


TickerCompany
ANEBAnebulo Pharmaceuticals, Inc.
SRZNSurrozen, Inc.
BDRXBiodexa Pharmaceuticals Plc
VRAXVirax Biolabs Group Limited
QNRXQuoin Pharmaceuticals, Ltd.
CVKDCadrenal Therapeutics, Inc. Common Stock
SABSSAB Biotherapeutics, Inc.
ONCROncorus, Inc.
PBLAPanbela Therapeutics, Inc.
VRPXVirpax Pharmaceuticals, Inc.
REVBRevelation Biosciences, Inc.
NRBONeuroBo Pharmaceuticals, Inc.
PRAXPraxis Precision Medicines, Inc.
MNPRMonopar Therapeutics Inc.
LABPLandos Biopharma, Inc.
PULMPulmatrix, Inc.
HILSTharimmune, Inc.
ALLRAllarity Therapeutics, Inc.
AKTXAkari Therapeutics, Plc
TARAProtara Therapeutics, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
VCNXVaccinex, Inc.

GTBP Ownership FAQ


GT Biopharma is owned by institutional shareholders (0.00%), insiders (6.67%), and public (93.33%). The largest institutional shareholder of GT Biopharma is RETIREMENT GROUP, LLC (0.00% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.03% of total shares).

GT Biopharma's major institutional shareholders are RETIREMENT GROUP, LLC, JPMORGAN CHASE & CO, BANK OF AMERICA CORP /DE/, WELLS FARGO & COMPANY/MN, and NORTHERN TRUST CORP. The top five shareholders own together 0.00% of the company's share outstanding.

As of Mar 2024, there are 1 institutional shareholders of GT Biopharma.

RETIREMENT GROUP, LLC owns 1 shares of GT Biopharma, representing 0.00% of the company's total shares outstanding, valued at $4 (as of Mar 2024).

As of Mar 2024, JPMORGAN CHASE & CO holds 0 shares of GT Biopharma (GTBP), compromising 0% of the company, valued at $0.

BANK OF AMERICA CORP /DE/ is the third largest holder of GT Biopharma. The company owns 0 of the company's shares outstanding (worth $0).